3SBio is a publicly listed company tracked for investment-relevant business developments.
Pfizer is tapping Chinese biotech innovation through licensing deals like 3SBio, but Bourla views this as transitional since Chinese companies will eventually take molecules global independently, leveraging half the cost and 3x speed of Western peers.